We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · April 07, 2021

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin ± Panitumumab for Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer


Additional Info

Clinical Genitourinary Cancer
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study
Clin Genitourin Cancer 2021 Feb 24;[EPub Ahead of Print], S Culine, A Fléchon, G Gravis, G Roubaud, Y Loriot, F Joly, P Barthélémy, E Assaf, H Mahammedi, P Beuzeboc, N Houédé, F Rolland, A Guillot, M Gross-Goupil, JP Spano, S Tartas, M Deblock, C Chevreau, C Serrate, H Manduzio, M Habibian, S Thézénas, Y Allory

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading